Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:38 ET | 537 | 0.6925 |
09:39 ET | 12815 | 0.696 |
09:41 ET | 300 | 0.6793 |
09:43 ET | 100 | 0.695833 |
09:48 ET | 284 | 0.695 |
09:50 ET | 100 | 0.695 |
09:54 ET | 1200 | 0.69 |
09:59 ET | 1300 | 0.6794 |
10:06 ET | 560 | 0.669401 |
10:10 ET | 370 | 0.6741 |
10:12 ET | 8103 | 0.688 |
10:17 ET | 252 | 0.6874 |
10:24 ET | 2100 | 0.6801 |
10:28 ET | 100 | 0.684 |
10:33 ET | 100 | 0.68 |
10:35 ET | 3700 | 0.6808 |
10:37 ET | 100 | 0.68365 |
10:42 ET | 200 | 0.6801 |
10:51 ET | 2400 | 0.68001 |
11:09 ET | 2640 | 0.6801 |
11:11 ET | 1600 | 0.68 |
11:15 ET | 100 | 0.68355 |
11:44 ET | 2292 | 0.68 |
11:49 ET | 305 | 0.6868 |
12:00 ET | 807 | 0.680001 |
12:05 ET | 2840 | 0.6801 |
12:07 ET | 100 | 0.68 |
12:14 ET | 100 | 0.68 |
12:21 ET | 2000 | 0.68 |
12:36 ET | 100 | 0.68 |
12:50 ET | 900 | 0.6869 |
12:52 ET | 1000 | 0.68 |
01:21 ET | 270 | 0.68 |
01:28 ET | 998 | 0.6801 |
01:35 ET | 200 | 0.68335 |
01:57 ET | 150 | 0.6801 |
02:11 ET | 500 | 0.6864 |
02:15 ET | 300 | 0.6826 |
02:20 ET | 100 | 0.68 |
02:22 ET | 10000 | 0.6832 |
02:24 ET | 3084 | 0.68 |
02:44 ET | 500 | 0.679 |
02:47 ET | 750 | 0.6717 |
02:51 ET | 1335 | 0.6717 |
02:54 ET | 100 | 0.6774 |
03:20 ET | 100 | 0.6745 |
03:32 ET | 9640 | 0.6718 |
03:34 ET | 1500 | 0.6694 |
03:38 ET | 1000 | 0.6694 |
03:57 ET | 2073 | 0.6701 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 24.1M | -1.9x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 4.8M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
CASI Pharmaceuticals Inc | 48.5M | -1.6x | --- |
Bon Natural Life Ltd | 8.7M | 0.4x | +78.05% |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.1M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.81 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -1.9x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.